Technical Analysis for EIGR - Eiger BioPharmaceuticals, Inc.
| ADX | Long Term | Intermediate Term | Short Term |
|---|---|---|---|
| Strong | Down | Down | Up |
| Historical EIGR trend table... | |||
| Date | Alert Name | Type | % Chg |
|---|---|---|---|
| 20 DMA Resistance | Bearish | 0.29% | |
| Bollinger Band Squeeze | Range Contraction | 0.29% | |
| Up 3 Days in a Row | Strength | 0.29% | |
| Slingshot Bearish | Bearish Swing Setup | 1.85% | |
| Bollinger Band Squeeze | Range Contraction | 1.85% | |
| Bollinger Band Squeeze | Range Contraction | 4.10% | |
| Stochastic Reached Oversold | Weakness | 4.10% | |
| BB Squeeze + Lower Band Touch | Range Contraction | 4.10% | |
| Lower Bollinger Band Touch | Weakness | 4.10% | |
| Oversold Stochastic | Weakness | 4.10% |
Recent Intraday Alerts -- Get these alerts pushed to you via our Mobile App
| Alert | Time |
|---|---|
| 20 DMA Support | 7 minutes ago |
| Rose Above 20 DMA | 42 minutes ago |
| Rose Above Previous Day's High | 42 minutes ago |
| Up 1% | 42 minutes ago |
| Rose Above 20 DMA | about 22 hours ago |
Get this analysis on your stocks daily!
Let us help you stay on top of your investments. We will alert you to important technical developments on your
portfolio & watchlist.
Configure default chart indicators
Basic chart:
- Earnings date: 05/05/2021
Eiger BioPharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops a portfolio of late-stage drugs for orphan diseases. It offers Sarasar, which is used for the treatment of hepatitis delta; Exendin that is used for the treatment of hypoglycemia; and Bestatin, which is used for the treatment of pulmonary arterial hypertension and lymphedema. Eiger BioPharmaceuticals, Inc. was founded in 2008 and is based in Palo Alto, California.
Sector: Healthcare
Industry: Biotechnology
Keywords: Biotechnology Biopharmaceutical Life Sciences Pharmaceutical Industry Pharmacy Hypertension Specialty Drugs Pulmonary Arterial Hypertension Hepatitis Biopharmaceuticals Orphan Disease Orphan Diseases Pulmonary Hypertension Treatment Of Hepatitis Hypoglycemia Lymphedema
Classification
Sector: Healthcare
Industry: Biotechnology
Keywords: Biotechnology Biopharmaceutical Life Sciences Pharmaceutical Industry Pharmacy Hypertension Specialty Drugs Pulmonary Arterial Hypertension Hepatitis Biopharmaceuticals Orphan Disease Orphan Diseases Pulmonary Hypertension Treatment Of Hepatitis Hypoglycemia Lymphedema
| Indicator | Bull Case | Neutral / Hold | Bear Case |
|---|---|---|---|
| 50 DMA | |||
| 200 DMA | |||
| ADX Trend | |||
| Oversold / Overbought | |||
| Relative Strength |
| Indicator | Value |
|---|---|
| 52 Week High | 13.99 |
| 52 Week Low | 6.76 |
| Average Volume | 201,711 |
| 200-Day Moving Average | 10.02 |
| 50-Day Moving Average | 9.59 |
| 20-Day Moving Average | 8.53 |
| 10-Day Moving Average | 8.33 |
| Average True Range | 0.46 |
| ADX | 36.86 |
| +DI | 16.08 |
| -DI | 25.40 |
| Chandelier Exit (Long, 3 ATRs ) | 8.10 |
| Chandelier Exit (Short, 3 ATRs ) | 9.23 |
| Upper Bollinger Band | 9.08 |
| Lower Bollinger Band | 7.97 |
| Percent B (%b) | 0.47 |
| BandWidth | 13.10 |
| MACD Line | -0.34 |
| MACD Signal Line | -0.39 |
| MACD Histogram | 0.0535 |
| Pivot Point Level | Traditional / Classic | Fibonacci | Demark | Woodie | Camarilla |
|---|---|---|---|---|---|
| Resistance 4 (R4) | 9.05 | ||||
| Resistance 3 (R3) | 9.02 | 8.80 | 8.95 | ||
| Resistance 2 (R2) | 8.80 | 8.66 | 8.82 | 8.92 | |
| Resistance 1 (R1) | 8.65 | 8.57 | 8.73 | 8.68 | 8.89 |
| Pivot Point | 8.43 | 8.43 | 8.47 | 8.45 | 8.43 |
| Support 1 (S1) | 8.28 | 8.29 | 8.36 | 8.31 | 8.09 |
| Support 2 (S2) | 8.06 | 8.20 | 8.08 | 8.06 | |
| Support 3 (S3) | 7.91 | 8.06 | 8.03 | ||
| Support 4 (S4) | 7.94 |
